Compare AstraZeneca plc (AZN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs NEOS S&P 500 High Income ETF — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while NEOS S&P 500 High Income ETF trades at $53.66. The key difference: AstraZeneca plc pays a 1.92% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SPYI | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $54.07 |
52-Week Low | $137.44 | $47.98 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SPYI trades at $53.37, down 0.61% on the day, with a bullish technical signal supported by moving averages. The NEOS S&P 500 High Income ETF has surpassed $10 billion in assets under management, driven by strong investor demand for its monthly income strategy. Recent dividend payments of $0.52-$0.54 demonstrate consistent distribution capabilities, while technical indicators show support at $53 and resistance at $54.
The ETF's covered-call strategy provides high monthly income with partial upside participation, making it attractive for income-focused investors. However, the 0.68% expense ratio and potential return of capital distributions present cost considerations. Market volatility benefits the options strategy, though competition with JEPI and other income ETFs remains a key factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
